Abstract-Although renal transplantation improves survival, cardiovascular morbidity and mortality remain significantly elevated compared with nonrenal populations. The negative impact of traditional, uremia-related, and transplantationrelated risk factors in this process remains, however, largely unexplored. Surrogate markers such as aortic stiffness and central wave reflections may lead to more accurate cardiovascular risk stratification, but outcome data in renal transplant recipients are scarce. We aimed to establish the prognostic significance of these markers for fatal and nonfatal cardiovascular events in renal transplant recipients. Carotid-femoral pulse wave velocity, central augmentation pressure, and central augmentation index were measured in a cohort of 512 renal transplant recipients using the SphygmoCor system. After a mean follow-up of 5 years, 20 fatal and 75 nonfatal cardiovascular events were recorded. Using receiver operating characteristic curves, the area under the curve for predicting cardiovascular events was 0. Key Words: cardiovascular events Ⅲ mortality Ⅲ pulse wave velocity Ⅲ augmentation pressure Ⅲ augmentation index Ⅲ transplantation Ⅲ kidney A lthough the survival advantage offered by successful renal transplantation 1 in large part can be attributed to a long-term reduction of the cardiovascular (CV) disease progression and mortality, 2 the annual risk of CV death still remains Ϸ50-fold higher than in the general population. 3 Nevertheless, CV death rates in transplanted patients are reduced by approximately 75% compared with wait-listed patients remaining on dialysis. 4 This decrease in CV risk by partial restoration of kidney function can be offset by the emergence or worsening of other risk factors due to transplant-specific causes, such as acute rejection, infection, or side effects of immunosuppressive drugs, including newonset diabetes after transplantation (tacrolimus, steroids), dyslipidemia (calcineurin inhibitors, mammalian target of rapamycin inhibitors), and anemia (mammalian target of rapamycin inhibitors). Part of the CV risk after transplantation may also relate to irreversible vascular damage accrued during the pretransplantation period.
A lthough the survival advantage offered by successful renal transplantation 1 in large part can be attributed to a long-term reduction of the cardiovascular (CV) disease progression and mortality, 2 the annual risk of CV death still remains Ϸ50-fold higher than in the general population. 3 Nevertheless, CV death rates in transplanted patients are reduced by approximately 75% compared with wait-listed patients remaining on dialysis. 4 This decrease in CV risk by partial restoration of kidney function can be offset by the emergence or worsening of other risk factors due to transplant-specific causes, such as acute rejection, infection, or side effects of immunosuppressive drugs, including newonset diabetes after transplantation (tacrolimus, steroids), dyslipidemia (calcineurin inhibitors, mammalian target of rapamycin inhibitors), and anemia (mammalian target of rapamycin inhibitors). Part of the CV risk after transplantation may also relate to irreversible vascular damage accrued during the pretransplantation period.
These numerous potential risk factors, together with the small number of randomized trials, render the management of CV risk in renal transplant recipients (RTRs) particularly difficult, whereas this population represents one of the largest groups of patients with chronic kidney disease regularly seen by the nephrologist. Therefore, surrogate markers of arterial damage, such as aortic stiffness and central wave reflections, have gained increasing interest for the assessment of overall CV risk in this heterogeneous population. Patient and donor characteristics that have been related to measures of arterial stiffness or wave reflection include donor age, 5 graft function, 6 ,7 microinflammation, 7 new-onset diabetes after transplantation, 8 hypomagnesemia, 9 and use of cyclosporine. 10 However, these cross-sectional relationships are only relevant if the presumed (extrapolated) prognostic significance of these indices is confirmed by outcome data within this specific population. Apart from 1 recent study on the predictive value of pulse wave velocity (PWV), 11 prospective data with hard end points in RTRs remain scarce, particularly for parameters of wave reflection. Therefore, in the present study, we aimed to establish the prognostic significance of parameters of wave reflection when combined with PWV, for the occurrence of fatal and nonfatal CV events in a large cohort of RTRs.
Methods

Patients
The study was conducted at 2 university hospitals in the Belgian cities of Ghent and Brussels. All prevalent RTRs with a functional graft attending the outpatient clinics of the Ghent University Hospital (Ghent) and the Saint-Luc Academic Hospital (Brussels) between February 1, 2004 , and January 31, 2006, were eligible for the study. Inclusion criteria were age Ն18 years and time after transplantation Ն3 months. Combined organ transplants and patients under treatment for malignancy (except nonmetastatic cutaneous cancers) were excluded. The study was approved by the local research ethics committees, and written informed consent was obtained from each participant.
Assessment of Arterial Stiffness and Wave Reflection
All measurements were performed by 2 trained investigators (Ghent: F.V.; Brussels: Pauline Nguyen). Blood pressure was recorded in the dominant or nonfistula arm using a validated oscillometric device (Omron M4-I, Omron Corp). Radial artery pressure waves were obtained from applanation tonometry with a high-fidelity micromanometer (SPC-301, Millar Instruments), calibrated on the brachial systolic and diastolic blood pressure. From these radial waveforms, a corresponding central wave was reconstructed by the application of a validated generalized transfer function 12 (SphygmoCor software, version 7, AtCor Medical). The integral system software calculated the central augmentation pressure (CAP) as the difference between the second and first systolic peaks, and the central augmentation index (CAI) as CAP divided by central pulse pressure (CPP).
Aortic PWV was measured with the same device by sequentially recording ECG-gated carotid and femoral artery pressure waves, using the intersecting tangent algorithm to determine the characteristic points. The path length was calculated as 80% of the direct distance measured between the carotid and femoral measurement sites, as recommended by the Reference Values for Arterial Stiffness' Collaboration group. 13 PWV was calculated as the path length divided by transit time (m/s).
Laboratory Measurements
Hematocrit and serum levels of calcium, phosphorus, total cholesterol, high-density lipoprotein cholesterol, and parathyroid hormone were determined using standard methodology. High-sensitivity C-reactive protein (CRP) was measured with the Roche particleenhanced immunoturbidimetric assay (Roche Diagnostics GmbH, Mannheim, Germany) at one site and with the Dade-Behring nephelometric assay (Dade-Behring, Deerfield, IL) at the other. Deming regression analysis has been shown good concordance between these 2 assays. 14 
Follow-Up
Patients were followed for the occurrence of fatal and nonfatal CV events, recorded from review of hospital medical charts and systematic telephone contact with each referring nephrologist. CV events were defined as myocardial infarction, coronary revascularization, acute pulmonary edema, stroke, transient ischemic attack, revascularization for peripheral vascular disease or aortic aneurysm, and sudden death. When multiple events occurred in the same patient, only the time to the first event was analyzed.
Statistical Analysis
Data are presented as means, medians, or percentages, as appropriate. Differences in risk factors between patients with and without an event were tested using the 2 statistic for discrete variables and the t test or the Wilcoxon rank-sum test for continuous variables, depending on the distribution. Receiver operating characteristic curves were used to compare the discriminative power of PWV, CAP, and CAI when used as a single parameter to predict outcome. Kaplan-Meier cumulative-event curves according to tertiles of PWV and CAP were constructed to describe the frequency of events according to time since baseline measurements and compared by the Mantel (log-rank) test. Hazard ratios and their 95% CIs were calculated using Cox proportional hazards models to estimate the independent relationship with outcome of PWV and CAP/CAI, analyzed as continuous variables. The parameter of wave reflection included in the final model was based on statistical criteria where CAP and CAI were allowed to compete in a stepwise Cox-regression procedure that also included PWV, age, and gender. After forcing PWV, CAP, age, and gender into the model, we allowed any of the following variables to enter the model in a stepwise forward selection procedure based on the likelihood ratio test: center, length, weight, body mass index, current smoking status, diabetes, mean arterial pressure, heart rate, time after transplantation, hemoglobin, serum calcium, phosphorus, calcium-phosphorus product, parathyroid hormone, total cholesterol, high-density lipoprotein cholesterol, CRP, treatment with angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers, statins, and cyclosporine. Analyses with and without history of CV disease were compared with verify the consistency of our results. We chose not to include CV history in the final model because (1) it is a rather crude dichotomous measure lacking information on type, number of events, and timing in relation to the start of the study; and (2) the validity of a statistical model that contains a variable that at the same time is a predictor of outcome and an outcome parameter as such may be questioned. The model assumption of proportionality of hazards was verified by plotting the partial residuals against time and testing for models including time-dependent covariates.
In a secondary analysis, we assessed the predictive value and discrimination of models based on standard CV risk factors with and without PWV and CAP. The selection of covariates was based on the components of the European SCORE project and included age, gender, total cholesterol, current smoking, and systolic blood pressure. The predictive value of the different models was assessed by using the likelihood ratio test, the Akaike information criterion, and the Bayesian information criterion; the latter 2 tests account for the number of predictors in the model. For all models, we computed the C statistic as the area under the receiver operating characteristic curve of predicted probabilities. We also computed net reclassification improvement using 3 categories of risk. Cut points for different categories were obtained as follows. First we computed predicted risk for all patients using a Cox model that included only standard risk factors. Using these predicted risks, we then defined cut points for risk groups based on tertiles of predicted risk in patients who experienced an event within 5 years, resulting in a uniform distribution of events across risk categories. We cross-classified risk categories based on the model that included only standard risk factors against those based on the model that added PWV and CAP. Cross-classification was assessed separately in patients who did or did not experience an event. Statistical analyses were performed with SPSS 15.0 software, and all tests were 2-sided.
Results
Between February 2004 and February 2006, 512 RTRs were included. Most patients were white (98%), and maintenance immunosuppressive regimens consisted of various combinations of azathioprine (25%), mycophenolate mofetil (55%), cyclosporine (47%), tacrolimus (35%), and sirolimus (12%). Steroids were part of the immunosuppressive regimen in 84% of patients. After a mean follow-up of 5 years, 20 fatal and 75 nonfatal CV events were recorded. Table 1 shows the characteristics and hemodynamic parameters of patients with and without events.
Using receiver operating characteristic curves, the area under the curve for predicting CV events was 0.718 for PWV, 0.670 for CAP, and 0.595 for CAI (Figure 1 ). Based on the numerically better area under the curve for CAP as compared with CAI, the former parameter of wave reflection was used to construct survival curves. Unadjusted Kaplan-Meier cumulative-event curves according to tertiles of PWV and CAP are shown in Figure 2 .
In multivariate Cox-regression analysis including age, gender, and PWV, the stepwise regression procedure preferred CAP over CAI as variable of wave reflection. CRP was an additional independent predictor of outcome. Both PWV and CAP independently were associated with an increased risk for a first CV event, with hazard ratios of 1.35 (95% CI: 1.10 -1.65; Pϭ0.003) and 1.49 (95% CI: 1.22-1.81; PϽ0.001) per SD increase in PWV and CAP, respectively. The final model is displayed in Table 2 . Including history of CV disease in the multivariate Cox-regression model had only a minor effect on the parameter estimates of CRP, PWV, and CAP without changing the overall conclusions (data not shown). No center effect was observed, and forcing center into the model did not alter the regression coefficients of the other covariates (data not shown).
When PWV and CAP were added to a base model that included age and gender, measures of model performance improved to a degree that was slightly better than adding the full set of standard risk factors to the base model ( Table 3 ). The addition of PWV and CAP to the risk factor-adjusted model resulted in a further improvement of model fit as indicated by reductions in log likelihood, the Akaike information criterion, and the Bayesian information criterion. The C statistic increased with 1% from 0.781 to 0.791. The addition of PWV and CAP resulted in upward reclassification of 14.7% of patients who experienced an event and a downward reclassification of 1.2% of patients who did not experience an event, yielding a net reclassification improvement of 15.9% (Pϭ0.03; Table 4 ).
Discussion
In contrast to the abundance of cross-sectional studies on arterial stiffness and wave reflections in renal populations, only a paucity of outcome data are currently available, and they mostly refer to PWV (only) and to dialysis populations. 15, 16 The present study provides the first direct evidence in RTRs that not only aortic stiffness but also central wave reflection are predictors for fatal and nonfatal CV events, extending the available evidence from the dialysis population to patients with a kidney transplant. It is also the first study to confirm in nondialyzed patients that stiffness and wave reflection both contribute independently to adverse central hemodynamic effects as has been shown in hemodialysis patients. 17 Therefore, the results of the present study support the recommendation of an expert consensus document to measure PWV-derived as well as pulse wave analysisderived parameters (such as CAP and CAI) to determine the contribution of aortic stiffness to wave reflections. 18, 19 Finally, we also demonstrated that prognostic value of CAP as a parameter of wave reflection is numerically and statistically superior to CAI. There may be several reasons for this. First, 
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because CAI is calculated as CAP/CPP, the resulting index is determined not only by wave reflection (CAP) but also by proximal aortic compliance and stroke volume (CPP). Second, in contrast to the linear age-related increase of CAP, changes in CAI with ageing are nonlinear and are more prominent at less than 50 years of age, 7, 20 which is an analytic disadvantage when age related effects have to be accounted for in statistical modeling. Third, CAI is a calculated dimensionless parameter that may be negative, whereas CAP is a measured pressure that allows a more straightforward interpretation. Although aortic stiffness and peripheral wave reflections both lead to an increased CPP, which is the resulting pulsatile load to the myocardium, discrimination between these 2 mechanisms may be relevant for prognostic and therapeutic reasons. A high CPP due to an increased aortic PWV indicates a loss of cushioning function of the central (proximal) aorta, whereas a high CPP due to pressure augmentation (but with a normal PWV) rather points to a disturbance at a more distant level in the circulation, resulting in an increased peripheral resistance.
Overall, mean values of PWV and CAP may seem somewhat lower than those reported in other high-risk populations.
This may be due to the fact that RTRs are a selected group of patients considered suitable for transplantation based on prior CV evaluation. Also, absolute values of PWV should be interpreted in relation to blood pressure, which was well controlled in the present cohort. Nevertheless, it has been shown that these parameters are significantly higher compared with healthy controls, matched for age, gender, and blood pressure. 7 The underlying mechanisms contributing to arterial stiffening and increased wave reflection are complex and incompletely understood. In RTRs, in addition to the adverse effects of immunosuppressive drug regimens on traditional CV risk factors, specific transplantation-related mechanisms have been implicated in subclinical damage of the large arteries. An independent relationship between level of transplant kidney function and indices of arterial stiffness 7, 21 has been reported, suggesting a role of uremic retention solutes with known vasculotoxic effects such as homocysteine, asymmetrical dimethylarginine, inorganic phosphate, phenylacetic acid, or dinucleoside polyphosphates. 22 More recently, a direct link between decreased serum levels of Fetuin-A (a calcification inhibitor), aortic calcification, and CV outcome has been demonstrated in RTRs. 23 Increasing evidence supports the hypothesis that medial wall calcification is an important factor contributing to aortic stiffness, although studies comparing both calcification and stiffness in RTRs are not available. Calcineurin inhibitors, still a cornerstone in many immunosuppressive drug regimens, exert dose-dependent renal and systemic vasoconstrictive effects and may increase peripheral wave reflection. 10 A remarkable independent association between donor age and PWV has been reported by Delahousse et al. 5 We did not evaluate donor age, as transplant kidney allocation in our unit is influenced by active matching between donor and acceptor age, thus creating collinearity.
We previously reported an independent relationship between high-sensitivity CRP and PWV/augmentation index. 7 In the present study, high-sensitivity CRP remained an independent predictor of CV events, indicating that the adverse effect of microinflammation is only partially explained by its relationship with pulsatile hemodynamics. Low-grade inflammation in RTRs may represent a residual effect from before transplantation or be due to sources other than those encountered in the dialysis stage, such as chronic allograft nephropathy, 24 periodontal disease, 25 or treatment with sirolimus. 26 In view of the adverse impact of subclinical inflammation, these sources should be searched for and remediated if present. Besides specific sources of inflammation, microinflammation may also be primarily an indicator of sustained arterial damage due to atherosclerosis. This is supported by a study of Varagunam et al, 27 in which pretransplantation CRP was an independent predictor of CV and all-cause mortality after transplantation.
In contrast to other populations, in the current cohort of RTRs, smoking status and total cholesterol were not independent predictors of outcome, whereas CRP emerged as a strong predictor in all models. Moreover, the addition of PWV and CAP to a model based on the components of the SCORE risk chart improved discrimination and net reclassification. This is not unexpected, as risk score algorithms such as the Framingham Risk Score and the corresponding European SCORE system have never been validated in renal populations. Therefore, clinicians in charge of RTRs should resist the temptation to estimate risk based on (components of) these risk scores. On the other hand, our data are in line with recent population-based studies in subjects without prior CV disease, showing that risk prediction is improved when adding PWV to these risk scores. 28, 29 The present study had several limitations. We studied a prevalent cohort of patients with variable time since transplantation, and no data on PWV or CAP/CAI from before transplantation were available, but obtaining longitudinal data would have required considerably more time to come to relevant results. The majority of our patients received a cadaveric kidney, so that care should be taken in extrapolating the results to acceptors of living donation. Finally, this was a noninterventional study, so treatment effects could not be evaluated. Nevertheless, it should be noted that the predictive value of PWV and CAP/CAI was not affected by type of immunosuppressive regimen, previous kidney transplantation, or living versus cadaveric transplant. The calibration of radial pressure waveforms with brachial artery pressures as advocated in the user manual of the SphygmoCor device may lead to some error in the assessment of central blood pressure and CAP. 30 Because this error is present in all patients' data and is expected to be proportional, it will not influence the conclusions of the present study. On the other hand, the strengths of our study include the large patient number, the use of noninvasive methodology, and the strong and independent predictive value of the parameters obtained for adverse outcome in this particular population.
Perspectives
Carotid-femoral PWV and CAP provide complementary predictive information for the occurrence of fatal and nonfatal CV events in RTRs, and they may help to identify patients at high risk. In such patients, traditional risk factors should be treated aggressively, and immunosuppressive drugs with less direct or indirect vasculotoxic side effects should be preferred. These patients may also require more regular preventive diagnostic CV evaluation. In patients at low CV risk according to PWV and CAP, the more common immunologically directed approach focused on minimizing the risk of rejection may be more appropriate. In addition, these parameters may also improve stratification according to baseline CV risk in interventional trials and thus may serve both scientific and clinical purposes. Major advantages over several other potential surrogate markers are the noninvasive nature of the technique, the minor discomfort for the patient, the limited time needed to obtain the measures, and the 
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relatively low cost compared with traditional ultrasonographic or radiographic equipments. The outcome data of the present study further add to the rapidly accumulating evidence on the strong, consistent, and independent predictive value of these measures for hard end points and support the adoption of PWV as marker of target organ damage in the most recent European Society of Hypertension guidelines. 31 Future studies should determine the optimal cutoff values in specific populations, such as RTRs, and provide thresholds for diagnostic and therapeutic interventions, such as changing the immunosuppressive regimen.
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